An­a­lysts spot­light the win­ners — and losers — on AS­CO pre­view night

AS­CO 2019 got start­ed with a bang on Wednes­day night as a hand­ful of biotechs co­or­di­nat­ed a se­ries of ab­stract drops and state­ments up­dat­ing an­a­lysts and in­ves­ti­ga­tors on their da­ta for some close­ly watched drugs. The big news still awaits us in Chica­go, but some ear­ly snap­shots on re­sults have whipped up some fer­vor for — and against — some of the biotechs mak­ing the trip.

Macro­Gen­ics emerges as the star of the ab­stract show

One of the big win­ners was Macro­Gen­ics  $MGNX,  which up­dat­ed the on­col­o­gy world on mar­ge­tux­imab, its Fc en­gi­neered an­ti-HER2 an­ti­body for breast can­cer. The ab­stract and a re­lease not­ed a par­tic­u­lar suc­cess for a sub­set of pa­tients, though it’s a very, very big sub­set.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER